NeOnc Executives Buy $629k in Stock Following Positive Brain Cancer Trial Results

Key Facts

1NeOnc's CEO and other executives purchased approximately $629,000 worth of shares in the open market.

2The purchases follow positive Phase 2a results for NEO100, a therapy for central nervous system cancers.

In a move reflecting optimism toward innovative central nervous system cancer treatments, executives at NeOnc Technologies Holdings purchased approximately $629,000 worth of shares in the open market. These purchases, involving the CEO and other senior leadership, follow positive Phase 2a clinical results for NEO100, a therapy targeting brain cancers. According to reports, this insider activity serves as a significant confidence signal regarding the company's clinical prospects following the successful trial data.

This insider buying occurs as biotech investors increasingly look for internal validation of research pipelines. Per market data, NTHI shares closed at $3.31 on September 15, 2026, having traded between a daily high of $3.8 and a low of $3.2. The executive purchases, executed at a weighted average price of approximately $3.30 per share, underscore management's commitment to the company's valuation following the encouraging clinical milestones.

Traders are currently watching for NTHI to maintain its levels above recent support, with the stock priced at $3.31 (close September 15, 2026). In the absence of major upcoming sector-specific catalysts in the economic calendar, market attention will remain focused on further SEC Form 4 filings and any regulatory updates regarding the FDA path for the NEO100 candidate.